Maker of life-science research reagents/instruments (PCR, chromatography) and clinical diagnostics test systems.
Maker of life-science research reagents/instruments (PCR, chromatography) and clinical diagnostics test systems.
Sells instruments to labs and then earns repeatedly on the reagents and quality-control materials they use, which gives recurring revenue. Clinical diagnostics is the bigger segment. The company holds a large stake in Sartorius, a German lab-equipment maker, which produces large unrealized gains or losses in reported profit. The Schwartz family controls the votes through Class B shares.
Moat: narrow (installed base, switching costs, IP / patents). Digital PCR and diagnostics quality-control franchises have loyal, workflow-embedded customer bases.
Headquarters: Hercules, California, USA · Founded: 1952 · Employees: 7,450
Size Bio-Rad Laboratories (BIO) is a United States Health Care company (Medical Specialties) with a market value of $10.1B, the 763rd largest of 3,085 United States companies the cockpit tracks. Shares closed at $370.17 on 18 Nov 2026.
Performance Over six months the shares gained 28.6%, against +30.7% for the median peer and -2.2% for the United States market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 1.4% over the last twelve months (peer median +7.2%); the operating margin is 9.5% (peer median 14.6%).
Valuation It trades at 34.6× forward earnings against a peer median of 19.9× (4th most expensive of 21).
Price implies For today's price to make sense, revenue must grow about 26% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +26 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 7.1 points below its cost of capital (9.8% WACC).
Credit Bio-Rad Laboratories has 2 bonds outstanding ($1.20B), rated BBB by the agencies and trading like BBB at a weighted spread of 106 bp.
Short interest Short interest is 5.3% of the free float (30 Oct 2026).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.59B | $2.58B | $2.57B | $2.67B | $2.80B |
| Revenue growth | — | +1% | -4% | -5% | — |
| Gross profit | $1.35B | $1.34B | $1.38B | $1.43B | $1.57B |
| EBITDA | $450M | $472M | $504M | $576M | $657M |
| Net income | $1.02B | $760M | -$1.84B | -$637M | -$3.63B |
| Free cash flow | $329M | $375M | $289M | $218M | $1.32B |
| Capital expenditure | $139M | $158M | $166M | $157M | $114M |
| Total debt | $1.36B | $1.39B | $1.38B | $1.41B | $1.40B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Bio-Rad Laboratories BIO | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Danaher DHR | $161B | +34% | +6% | 21% | 25.1× | 20.8% |
| Bio-Techne TECH | $11.4B | +56% | +1% | 21% | 34.4× | 31.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | BIO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.4% | +6.1% | 10th lowest of 21 |
| 6-month return | +28.6% | +30.7% | 11th highest of 21 |
| Distance from 52-week high | -6.6% | -11.7% | 5th highest of 21 |
| Revenue growth (TTM) | +1.4% | +7.2% | 4th lowest of 21 |
| Operating margin | 9.5% | 14.6% | 5th lowest of 21 |
| Forward P/E | 34.6× | 19.9× | 4th most expensive of 21 |
| Growth the price implies (Req g, 7 yrs) | 26.0% | 9.4% | 3rd most demanding of 20 |
| Growth delivered (Del g) | +0.3% | +10.0% | 2nd lowest of 20 |
| Hurdle (Req g minus delivered) | +25.7 pp | +2.0 pp | most demanding of 20 |
| ROIC minus cost of capital | -7.1 pp | +2.4 pp | 2nd lowest of 21 |
| EV / EBITDA | 21.7× | 12.4× | 3rd most expensive of 19 |
| Net debt / EBITDA | -0.7× | 0.9× | 3rd least indebted of 19 |
| Bond spread | 106 bp | 113 bp | tightest of 5 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Bio-Rad Laboratories BIO | United States | $10.1B | +29% | +1% | 9% | 34.6× | 26.0% | +0.3% |
| Qiagen QGEN | United States | $10.2B | +41% | +2% | 25% | 19.5× | 8.6% | +2.2% |
| Demant A/S DEMANT.CO | Denmark | $10.4B | +39% | +10% | 18% | 23.2× | 5.8% | +9.8% |
| Insulet PODD | United States | $9.71B | -11% | +26% | 18% | 18.6× | 10.6% | +24.5% |
| Avantor AVTR | United States | $10.4B | +95% | +1% | 8% | 17.5× | 16.4% | +0.5% |
| Bruker BRKR | United States | $9.66B | +43% | +2% | 10% | 27.0× | 25.4% | +11.6% |
| Globus Medical GMED | United States | $9.34B | -16% | +13% | 23% | 13.7× | 4.6% | +30.1% |
| Cooper Companies (The) COO | United States | $11.6B | -2% | +5% | 19% | 13.4× | 9.4% | +11.0% |
| Align Technology ALGN | United States | $11.6B | 0% | +4% | 19% | 13.8× | 13.1% | +10.3% |
| bioMerieux BIM.PA | France | $11.8B | +26% | -3% | 15% | 20.2× | 8.6% | +5.5% |
| Shimadzu 7701.T | Japan | $8.14B | +24% | +8% | 14% | 21.0× | 8.3% | +7.3% |
| Sysmex 6869.T | Japan | $8.06B | +58% | +8% | 13% | 32.0× | 4.4% | +10.4% |
| Smith & Nephew SN..L | United Kingdom | $12.6B | +1% | +2% | 17% | 14.2× | 11.1% | +5.6% |
| Penumbra PEN | United States | $12.6B | -2% | +17% | 12% | 55.7× | 30.7% | +20.2% |
| Olympus 7733.T | Japan | $12.7B | +5% | +9% | 18% | 18.7× | -6.5% | +6.7% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.50B | +21% | +7% | 43% | 26.9× | 2.9% | +15.7% |
| Baxter International BAX | United States | $13.5B | +39% | +5% | 6% | 12.7× | 13.4% | -0.7% |
| Getinge GETI-B.ST | Sweden | $7.45B | +40% | -4% | 14% | 21.1× | 5.0% | +3.2% |
| Lenskart Solutions LENSKART.NS | India | $13.6B | +49% | +35% | 10% | 137.7× | 53.2% | +33.5% |
| Bausch + Lomb BLCO.TO | Canada | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% | +10.0% |
| Glaukos GKOS | United States | $13.8B | +62% | +47% | -9% | 161.5× | n/a | n/a |
Bio-Rad Laboratories has 2 bonds outstanding with $1.20B face value. The agencies rate it BBB; its bonds trade like BBB. Weighted yield 5.75%, a spread of 106 bp over government bonds.